A biotech business has launched in Oxford in a bid to tackle one of the world’s rarest diseases.
SynaptixBio is working to develop a disease-modifying treatment for TUBB4a leukodystrophy, including H-ABC – a debilitating and potentially life-limiting neurodegenerative condition.
It causes hypomyelination in the brain, which can lead to developmental delays in motor skills such as walking, sitting, speaking and swallowing; learning difficulties, seizures, paralysis and an early death.
Read more at: https://www.insidermedia.com/news/south-east/oxford-biotech-firm-launches-to-tackle-rare-disease
